Viatris upgraded to Strong Buy on strong pipeline and growth prospects.

Viatris has been upgraded to a Strong Buy rating due to its robust pipeline catalysts and credible long-term growth plan. The company aims for a five-year sales CAGR midpoint of 3.5%, which surpasses market consensus, supported by $450–550 million in annual new product contributions and growth from branded assets. Key products like Selatogrel and Cenerimod, along with upcoming launches such as meloxicam, are expected to drive growth acceleration and margin expansion. Management forecasts $11 billion in cash generation through 2030 to support disciplined capital allocation, selective mergers and acquisitions, and a strategic shift toward higher-value generics.